The gene MAPT in this region, tagged by SNPs of the PD‐PRS, was already known as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first‐line chemotherapy and as a marker of paclitaxel sensitivity in breast cancer.1 The gene discussed is MAPT; the disease is ovarian carcinoma.